Catalog No.
DHJ85305
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
Fusion - [peptide 16-mer - peptide 19-mer]2 - IGHG1 Fc (Fragment constant)
Target
BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y275
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
A-623
Clone ID
Blisibimod
Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia., PMID:39062171
A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)., PMID:37755547
Advances in natural products and antibody drugs for SLE: new therapeutic ideas., PMID:37492083
Emerging B-Cell Therapies in Systemic Lupus Erythematosus., PMID:33488082
The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis., PMID:31777515
Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus., PMID:31565077
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial., PMID:29563108
Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis., PMID:28673504
Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art., PMID:28443384
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date., PMID:28331294
Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)., PMID:28164726
Biotherapies in systemic lupus erythematosus: New targets., PMID:27663753
Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod., PMID:27353505
Overview of pathophysiology and treatment of human lupus nephritis., PMID:27341623
Update on clinical trials in systemic lupus erythematosus., PMID:27314466
Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser., PMID:27051973
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials., PMID:26290435
B-cell survival factors in autoimmune rheumatic disorders., PMID:26288664
The European League Against Rheumatism (EULAR) - 16th Annual European Congress (June 10-13, 2015 - Rome, Italy)., PMID:26261853
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents., PMID:25609919
The efficacy of novel B cell biologics as the future of SLE treatment: a review., PMID:25149393
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study., PMID:24748629
Emerging biological therapies for systemic lupus erythematosus., PMID:24588398
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus., PMID:24521424
Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy., PMID:24226636
The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity., PMID:23684423
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?, PMID:22547203
A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease., PMID:22325420
For research use only. Not for human or drug use.
